iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM), have entered into a collaboration wherein CBM will produce and supply good manufacturing practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE’s future clinical studies. “Our approach to gene editing relies on highly complex manufacturing processes, and we are eager...